SHR-A1912 not checked

Hengrui

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Diffuse Large B-cell Lymphoma
Main trialPhase 3
“This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.”In the company’s words, NCT06929624 on ClinicalTrials.gov

Other drugs for Diffuse Large B-cell Lymphoma

All 86 drugs for Diffuse Large B-cell Lymphoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Mar 2027 A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Phase 1/2Unknown Dec 2025 A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Phase 1Unknown 31 Mar 2024 A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SHR-A1912

Following is part of Solo: you see every change to SHR-A1912 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in